NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX molecular thyroid test will now be covered by Cigna.
The test uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, and is designed to assess fine needle aspiration samples from indeterminate thyroid nodules.
According to Interpace, ThyGenX will now be covered for Cigna's roughly 15 million members nationwide, effective immediately. The test is already covered by Aetna, UnitedHealthcare, Medicare, and other payors, bringing the total number of covered lives in the US to about 275 million, the company added.